Hello,
I'm new to your forum, but not new to psoraisis, having dealt with it for, oh let's see, about 45 years. It was mostly an annoyance for about 35 of those, before it really got bad. So much better now, 1st with Remikade, and now Stelara.

If you don't like the way posts are shown with the profiles along the top of a post. you can revert back to the Classic view where profiles are shown on the left of posts. (Click image to enlarge)





To revert to classic view go to your User CP and on the left hand side click "Edit Options" then on the right under "Thread View Options" tick the box Display posts in classic mode. scroll down and click "Update Options"

If you want to go back to the modern view just untick the box again and update.

If you are trying to register for membership and you get the following message.

Quote:Your details match those of a known spammer, therefore you have been disallowed registration.

Quote:Im listed on your site but Im not a spammer
Firstly, its not an accusation of anything. A lot of the information that is listed is gathered from "honeypots" setup to trap spammers. Being listed on the site doesnt mean you have been sending spam. The IP address that you have, mightve been inherited from someone that spammed, someone may have just used your email address or even that you have downloaded a virus or trojan. If you use the removal page and be polite, then we can figure out what has happened and get it fixed.

AbGenomics International will regain global rights to AbGn-168H from Boehringer Ingelheim, with effect from 13 February 2012.

The move was made following the termination of collaboration between both the companies.

AbGn-168H, a humanized monoclonal antibody against CD-162 preferentially induces apoptosis of late-stage activated T-cells and is under development to treat psoriasis and other immunological diseases.

AbGenomics intends to carry on with the development of AbGn-168H in psoriasis as well as in other immune and inflammatory disease indications and hence will seek a new partner.

AbGenomics founder and CEO Rong- Hwa Lin said the company had a good collaboration agreement with Boehringer Ingelheim since 2005.

"While we will continue to develop AbGn-168H for psoriasis, regaining the global rights will also permit us to consider other indications that will take advantage of the full therapeutic potential of this drug," Hwa Lin added.

Source: pharmaceutical-business-review.com

Pulsed dye laser therapy may be an attractive new option for treating nail psoriasis, according to Dr. Veronique Blatiere.

Nail psoriasis is challenging to treat because the psoriatic disease process damages the nails while they are still being formed. But Turkish investigators have reported positive results with three once-monthly pulsed dye laser (PDL) treatment sessions in a small uncontrolled patient series, Dr. Blatiere reported at the annual congress of the European Academy of Dermatology and Venereology.

Dr. Yasemin Oram and coworkers at the American Hospital in Istanbul, Turkey, reported on five patients with nail psoriasis treated using PDL. The laser therapy was applied at 595 nm with a pulse duration of 1.5 milliseconds, a beam diameter of 7 mm, and an energy fluence of 8-10 J/cm2. A treatment session was continued until a purple discoloration appeared.

Nail bed lesions, particularly onycholysis and subungual hyperkeratosis, responded to PDL better than did nail matrix lesions. After three treatment sessions, the average Nail Psoriasis Severity Index (NAPSI) score for nail bed lesions dropped from 14.8 to 8.

While the Turkish report is certainly encouraging, it should be viewed as a proof of concept pilot study, said Dr. Blatiere of Saint Eloi University Hospital in Montpellier, France. It needs confirmation with larger numbers of patients, a control arm, and blinded investigator assessment.

Source: skinandallergynews.com

Hi, I have just joined. Will spend a bit of time just finding my way around before I say anything interesting. In the meantime nice to meet you all.

UCD clinician scientists and researchers from NUI Maynooth and Trinity College led by Conway Fellow, Professor Donal O’Shea have reported an improvement in the severity of psoriasis in patients following glucagon-like peptide-1 (GLP-1) analogue therapy. Their findings raise the possibility of therapeutic applications for GLP-1 in inflammatory conditions due to the direct impact on innate natural killer T (iNKT) cells.

The clinical team based in St Vincent’s University Hospital found an unexpected improvement in the severity of psoriasis in a patient with type 2 diabetes within days of starting GLP-1 analogue therapy. They surmised this was due to the direct action of GLP-1 on iNKT cells.

The team began treating two obese patients with type 2 diabetes and psoriasis with the GLP-1 analogue, liraglutide. Both patients experienced relief from their psoriasis symptoms within days of starting treatment and the psoriasis area and severity index (PASI) decreased in both.

Describing the laboratory findings, Dr. Andrew E. Hogan, UCD Newman Scholar and senior scientist said, “There was an alteration in iNKT cell number before and after commencing treatment; an increased number in the circulation and decreased number in psoriatic plaques. We also found that iNKT cells expressed GLP-1 receptor and modulated cytokine production”.

Professor Donal O’Shea believes that “Although extensive research will be required to investigate GLP-1 immune cell interactions, the potential benefit for inflammatory conditions such as psoriasis is promising”.

Source: medicalxpress.com

Enbrel treatment for psoriasis may be associated with an increased risk for multiple squamous cell carcinomas (SCCs), suggest results from a case series and review of the literature.

There is some prior evidence to suggest that anti-tumor necrosis factor drugs such as Enbrel may increase the risk for skin cancers such as SCC, but reports to date have been conflicting.

Writing in the International Journal of Dermatology, Jerry Brewer (Mayo Clinic, Rochester, Minnesota, USA) and colleagues describe four cases of patients with psoriasis and multiple SCCs thought to be a result of Enbrel treatment.

The patients in the series were aged 53 to 85 years and all had lifelong psoriasis. The mean time to first SCC onset was 11 months (range 1-17 months) after beginning Enbrel therapy, with all patients having between five and more than 50 SCCs in total and three of the four patients having aggressive grade III or IV SCCs.

The four psoriasis patients did not have a family history of skin cancer, but all four had previously had SCCs before using Enbrel.

Brewer and team reviewed the literature to evaluate previous reports of links between Enbrel and SCC. They found four further reports of psoriasis patients (n=10) who were treated with Enbrel going on to develop SCC, in one case in addition to non-Hodgkin lymphoma.

In contrast, another study found no increased risk for SCC with Enbrel treatment in 1440 patients with psoriasis. In addition, mice deficient in tumor-necrosis factor-α were shown to be resistant to skin cancer in a further study.

"Although some studies suggest there is no increased risk of cutaneous malignancy in patients treated with Enbrel, more research is needed to better characterize the effect of Enbrel on the development of SCCs in patients with psoriasis," say Brewer and co-authors.

"Until further research is available, sun-protective behavior, education into skin cancer prevention, and regular self-examinations and dermatologic examinations are warranted for patients with psoriasis treated with Enbrel," they conclude.

Source: medwire-news.md

I'm wondering if others have had this with their skin, I find it a little worrying!

I have found some strange patterns with my skin, dots going in lines across my body!!
My first lot was a diagonal line from my side (up near breast) comming down across my stomache towards my groin!
I have noticed it on the back of my thigh, and a new line of dots going from the bottom of my ear comming down diagonally accross my neck!!

I spoke to my skin nurse and explained that I had also hurt my hip on the side where the P was comming across stomache, she and a few others said that there is a nerve that runs there and my P was along that line.

I have Koebnerization (cuts turn to P) so can hurt nerves also cause P to come up?

Has anyone else seen similar to this? P along nerve area's
My other thought is that it's something work related.......getting jumped on by over excited dogs!!!

x

Sorry if you have this in old threads.

Is there a blood test that rules out P.A? Ill go online shortly...

I am questioning it because i am still nervous about going on drugs, as i may want to get pregnant.
My other question is If you don't have PA, then is the prognosis for
rheumatoid arthritis attacking the ligaments, tendons etc;. the same?
So, possibly one might buy some time without the drugs.

Thanks

Best regards,
LL

Just took a look at psoriasis dot org, an american website on psoriasis.
Did not get a well impression. The impression is more that is in fact is driven by pharmacy and that they have all cures and knowledge.
And you and I know that that is impossible and certainly not true.
Bit of an arrogant impression so to feel.

They also have a forum talkpsoriasis dot org, don't know if that is something valuable.

Just curious of anyone had any success with a particular medicine or protocol.

Thx

LL

private messages welcome.

Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.

“The agreement is part of our international commercialization of Emtrix®. As the leading Italian pharmaceutical group, ranked 34th in the world, Menarini is well positioned to make Emtrix® a success in Italy. Emtrix® will now be marketed in all large markets in Europe, in US and Australia”, says Peter Wolpert, President and CEO of Moberg Derma.

About Emtrix® and nail disease
Emtrix® is a topical treatment used to treat nail disease. Launched in the Nordic region in autumn 2010, it quickly became market leader. Emtrix® is a prescription free, over-the-counter product sold under the name Nalox™ in certain markets and under the name Kerasal® Nail in the U.S. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments.

About Moberg Derma
Moberg Derma AB (publ), based in Stockholm, develops patented topical pharmaceuticals for the treatment of common disorders through the use of innovative drug delivery. The company’s products are based on proven compounds, which reduce time to market, development costs and risk. Moberg Derma’s first product Nalox™/Emtrix® - for nail disorders - became the Nordic market leader directly after launch in autumn 2010 and international launch is ongoing. The portfolio includes approved and launched products to projects in the preclinical and clinical phase. The company began operations at the Karolinska Institute in Stockholm in 2006.

About Menarini Group
The Menarini Group celebrates it’s 125thAnniversary this year and is the leading Italian pharmaceutical group in the world, ranking 15thout of 4,881 companies in Europe*and 34thout of 14,051 companies in the world* (*Sources:  IMS World Review 2010, IMS World Review Pack 2010 per number of companies).  The Group’s 2010 global turnover was 3,031 million Euro. In 2010 the number of employees was 12,890 (91% of which graduates and technicians). The Menarini Group has always pursued two strategic objectives: Research and Internationalisation, both of which have allowed them to achieve outstanding results in today’s global market and to invest in the research of innovative drugs, making them available to patients all around the world.

Source: mobergderma.com

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Janssen Biotech, Inc. (formerly Centocor Ortho Biotech, Inc.) has initiated a phase 2 clinical trial in psoriasis patients with the HuCAL-derived antibody CNTO 1959. The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.


“With every clinical milestone and every new phase 2 start the time where the first HuCAL-based antibody drug could enter the market gets closer. MorphoSys’s antibody pipeline has substantially matured over the last 18 months,” commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.


In total, MorphoSys’s clinical pipeline now comprises nine partnered programs in phase 1 and seven in phase 2 development as well as the Company’s proprietary programs MOR103, which is in a phase 1b/2a trial for rheumatoid arthritis, MOR208, which is in a phase 1 trial for chronic lymphocytic leukemia and MOR202, which is in a phase 1/2a trial for multiple myeloma.


About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. The company’s AbD Serotec unit uses HuCAL and other antibody technologies to generate superior monoclonal antibodies for research and diagnostic applications.

Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow.

Source: morphosys.com

Hi all.
Although I don't suffer from it much myself now, it is in the family coming from my mothers side, I do get Psoriasis in my hair from time to time and find that shampooing it at least every two days holds it in check. Having a very positive attitude to life is very useful.
One product which I have discovered here in France is natural olive oil soap, not only for Psoriasis but any heat rash related fungal infections like under the arms. We have used soap nuts for all our washing for a number of years and thoroughly recommend it, another very good natural cream is Karite butter, in the UK it is known as shea butter very thick so mix with sweet almond oil. sourced from Akamuti
Sorry if I have repeated some things already online but have only just joined.

Just thought I would share,

I just has my 4th - first session of UVB

I hope I'm doing the right thing by having more, it's always scary when a treatment stops.

But I'm trying to stay positive, I gave up smoking 6 weeks ago and I'm hoping this with the UVB will give me a longer remission

(the top of my back started to clear a little while ago!!)


just one Q, can my work force me to change my day off to fit one of the treatments in? UVB clinic is mon and Thurs my day off is Tues I work weekends too!!


x

The most poisonous substance on Earth could be re-engineered for an expanded role in helping millions of people with rheumatoid arthritis, asthma, psoriasis and other diseases. Botox is already used medically in small doses to treat certain nerve disorders and facial wrinkles.

Edwin Chapman and colleagues explain that toxins, or poisons, produced by Clostridium botulinum bacteria, cause of a rare but severe form of food poisoning, are the most powerful toxins known to science.

Doctors can inject small doses, however, to block the release of the neurotransmitters, or chemical messengers, that transmit signals from one nerve cell to another. The toxins break down a protein in nerve cells that mediates the release of neurotransmitters, disrupting nerve signals that cause pain, muscle spasms and other symptoms in certain diseases. That protein exists not just in nerve cells, but in other cells in the human body. However, these non-nerve cells lack the receptors needed for the botulinum toxins to enter and work.

Chapman’s group sought to expand the potential use of the botulinum toxins by hooking it to a molecule that can attach to receptors on other cells.

Their laboratory experiments showed that these engineered botulinum toxins do work in non-nerve cells, blocking the release of a protein from immune cells linked to inflammation, which is the underlying driving force behind a range of diseases. Such botulinum toxin therapy holds potential in a range of chronic inflammatory diseases and perhaps other conditions, which could expand the role of these materials in medicine.

Get your favourite RSS reader. I use the Brief feed reader add-on with Firefox, but there are many others you can use and some email clients let you set them up.

Now you want your feeds. you can find them whilst on Psoriasis Club via your feed reader or you can click RSS Syndication at the foot of the home page and make your own. *Note: the latter will only find the thread version, to get the post version add 2 after syndication.

Now you choose which version you want:

This one gives you new threads: https://psoriasisclub.org/syndication.php?limit=15

This one gives you new posts: https://psoriasisclub.org/syndication2.php?limit=15

*Change the limit=** to the umber of threads/posts you want.

Click them and you will see the difference. *Note: Members only posts are shown if you are logged in. if you log out you will see the same as guests.

There you go you have the Psoriasis Club RSS feed.

Hi everyone,
Thought I would introduce myself and my Psoriasis story!!

I've had Psoriasis since I was 4years old (although after my flare cleared when I was 4 I only had it on my elbows for years)

When I was about 17 I had a major flare (I started training to be an aircraft engineer which was extremely stressful and my sister started to have suicidal tendencies another stress)

About the age of 20 my skin was doing well and was mainly affecting my knee's and elbows, but it wasn't to be for long

I'm now 26 and still covered in the stuff.

My treatments so far have been all the lotions and potions which turns out I'm allergic to pretty much all of them including things like E45 and diprobase, and any other cream starting with D
3 lots of UVB, 2 courses of methotrexate, and 2 courses of cyclosprin.
I'm starting another round of UVB on monday, I'm not expecting miricles just a little while of less vacumming!!

I left all my aircraft stuff behind as to stressful and I now work for an animal rescue center, I work with the dogs - training and rehoming and loving them.

I also have a wonderful Husband who is so supportive and helps me to stay strong in difficult times. I wouldn't say I'm totally depressed about my skin I don't mind so much especially in winter when it's ok to cover up I just need paper bags to come into fashion now for my face LOL

For me my challange now is just getting through the pain my skin brings me!


Hope to get to know some of you

Hanna x

When I'm Tweeting threads on @Psoriasisclub I sometimes like to think of something positive to tweet.

Here are a few I remember doing:

Quote:If I didn't have psoriasis I wouldn't know so many great people around the world

Quote:I may be flaky on the outside but just like you I'm soft in the middle

Quote:Psoriasis is not contagious you CAN use that shopping trolley after me. your hands will not fall off I promise!